Literature DB >> 26614665

Translational dysregulation in cancer: eIF4A isoforms and sequence determinants of eIF4A dependence.

Farheen Raza1, Joseph Alexander Waldron1, John Le Quesne2.   

Abstract

The malignant phenotype is largely the consequence of dysregulated gene expression. Transformed cells depend upon not just a global increase in protein synthesis but an altered translational landscape in which pro-oncogenic mRNAs are translationally up-regulated. Such mRNAs have been shown to possess longer and more structured 5'-UTRs requiring high levels of eukaryotic initiation factor 4A (eIF4A) helicase activity for efficient translation. As such there is a developing focus on targeting eIF4A as a cancer therapy. In order for such treatments to be successful, we must develop a detailed understanding of the mechanisms which make specific mRNAs more dependent on eIF4A activity than others. It is also crucial to fully characterize the potentially distinct roles of eIF4A1 and eIF4A2, which until recently were thought to be functionally interchangeable. This review will highlight the recent advances made in this field that address these issues.
© 2015 Authors; published by Portland Press Limited.

Entities:  

Keywords:  5′-untranslated region (5′-UTR); G-quadruplex; cancer; eukaryotic initiation factor 4A (eIF4A); mRNA helicase; translation

Mesh:

Substances:

Year:  2015        PMID: 26614665     DOI: 10.1042/BST20150163

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  22 in total

Review 1.  The DEAD-box protein family of RNA helicases: sentinels for a myriad of cellular functions with emerging roles in tumorigenesis.

Authors:  Mohamed A M Ali
Journal:  Int J Clin Oncol       Date:  2021-03-03       Impact factor: 3.402

Review 2.  Action and function of helicases on RNA G-quadruplexes.

Authors:  Marco Caterino; Katrin Paeschke
Journal:  Methods       Date:  2021-09-10       Impact factor: 4.647

3.  Programmed cell death 4 mechanism of action: The model to be updated?

Authors:  Polina N Vikhreva; Svetlana V Kalinichenko; Igor V Korobko
Journal:  Cell Cycle       Date:  2017-08-30       Impact factor: 4.534

Review 4.  Cancer the'RBP'eutics-RNA-binding proteins as therapeutic targets for cancer.

Authors:  Shakur Mohibi; Xinbin Chen; Jin Zhang
Journal:  Pharmacol Ther       Date:  2019-07-11       Impact factor: 12.310

5.  Transcriptional Biomarkers in Oral Cancer: An Integrative Analysis and the Cancer Genome Atlas Validation.

Authors:  Kinjal D Patel; Hemangini H Vora; Prabhudas S Patel
Journal:  Asian Pac J Cancer Prev       Date:  2021-02-01

6.  Restoration of type 1 iodothyronine deiodinase expression in renal cancer cells downregulates oncoproteins and affects key metabolic pathways as well as anti-oxidative system.

Authors:  Piotr Popławski; Jacek R Wiśniewski; Eddy Rijntjes; Keith Richards; Beata Rybicka; Josef Köhrle; Agnieszka Piekiełko-Witkowska
Journal:  PLoS One       Date:  2017-12-22       Impact factor: 3.240

Review 7.  Identification of novel MECOM gene fusion and personalized therapeutic targets through integrative clinical sequencing in secondary acute myeloid leukemia in a patient with severe congenital neutropenia: a case report and literature review.

Authors:  James A Connelly; Rajen J Mody; Yi-Mi Wu; Dan R Robinson; Robert J Lonigro; Pankaj Vats; Erica Rabban; Bailey Anderson; Kelly Walkovich
Journal:  Cold Spring Harb Mol Case Stud       Date:  2018-04-02

Review 8.  DEAD-Box RNA Helicases in Cell Cycle Control and Clinical Therapy.

Authors:  Lu Zhang; Xiaogang Li
Journal:  Cells       Date:  2021-06-18       Impact factor: 6.600

Review 9.  Translation initiation and its relevance in colorectal cancer.

Authors:  Emma Minnee; William James Faller
Journal:  FEBS J       Date:  2021-01-24       Impact factor: 5.622

10.  eIF4A alleviates the translational repression mediated by classical secondary structures more than by G-quadruplexes.

Authors:  Joseph A Waldron; Farheen Raza; John Le Quesne
Journal:  Nucleic Acids Res       Date:  2018-04-06       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.